Impact ledger

Lisata Therapeutics, Inc. (LSTA): the developments shaping its investment case

Follow the evidence affecting Lisata Therapeutics, Inc.'s valuation assumptions, demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

Research Lisata Therapeutics, Inc. · $399/mo

Test assumptions, examine opportunities, and save your research.

Material developments

2026-09-17 · 2 reports

Lisata Therapeutics, Inc. to Acquire Marea Therapeutics, Inc.

Channel: Direct impact from M&A transaction, dilution, and integration of new assets/liabilities.

mixed· 3-12m

Evidence affecting valuation assumptions

Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

Date	Assumption	Direction	Interpretation
2026-09-17	share_count	Bullish	Issuance of common and preferred stock for Marea acquisition and concurrent PIPE will increase total as-converted share count to approximately 396.3 million.
2026-09-17	share_count	Bullish	Total number of shares of Lisata common stock (including shares underlying the Series C non-voting convertible preferred stock) will be approximately 396,315,542 following the Marea acquisition and PIPE.
2026-09-17	multiple	Bearish	Incremental float typically compresses near-term multiple absent revenue acceleration.
2026-09-17	share_count	Bullish	Primary equity issuance increases diluted share count.
2026-09-17	share_count	Bullish	Stock component of consideration dilutes existing acquirer holders.
2026-09-17	net_debt	Bullish	Cash component of consideration is typically debt-funded, raising net debt.
2026-09-17	revenue	Bullish	Acquisition adds target revenue to acquirer P&L on close.
2026-07-03	net_debt	Bearish	Liability-management transactions often reduce gross debt or push maturities out.
2026-07-03	interest_expense	Bearish	Tender/exchange extends maturity profile and typically lowers near-term interest expense.
2026-06-12	multiple	Bullish	Target re-rates to bid premium until close.

Event impact log

2 events mapped to LSTA since 2026-09-17. Evidence through 2026-09-17.

Date	Event	Channel	Direction	Horizon	Impact
2026-09-17	Lisata Therapeutics, Inc. to Acquire Marea Therapeutics, Inc.	Direct impact from M&A transaction, dilution, and integration of new assets/liabilities.	mixed	3-12m	0.70
2026-09-17	Lisata Therapeutics, Inc. Follow-On — $225M	Dilution risk from convertible preferred stock, improved liquidity for operations and acquisition integration, potential for increased R&D or M&A activity.	mixed	1-3m	0.70

Continue this research

Build your Lisata Therapeutics, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.